An integrated Biobank in the Swedish Heart Failure Registry-clinomics, proteomics, transcriptomics and genomics

Area of Science:

• Cardiovascular Research
• Biobanking
• Precision Medicine

Background:

• The Swedish Heart Failure Registry (SwedeHF) is a leading global registry for heart failure (HF).
• Integrating multi-omic data with clinical registries is crucial for advancing HF research.

Purpose of the Study:

• To establish a comprehensive biobank linked to the SwedeHF registry.
• To collect clinomic, proteomic, transcriptomic, and genomic data alongside clinical and ICD-code information.
• To facilitate research into HF mechanisms, treatment response, and precision medicine.

Main Methods:

• Biobanking of blood and urine samples from HF patients at routine visits across nine hospitals.
• Optional second sampling at six months.
• Multi-omic profiling (proteomics, metabolomics, transcriptomics) and genetic analysis of samples.
• Targeting a sample size of 5000 patients, informed by BIOSTAT-CHF cohort data.

Main Results:

• The initial 1348 enrolled patients had a median age of 72 years, with 30% females, 65% HFrEF, and 11% HFpEF.
• Median NT-proBNP was 1240 pg/ml.
• Demographics and NT-proBNP levels were comparable to the broader SwedeHF registry data from 2023.

Conclusions:

• A high-quality biobank is being developed, integrated with the SwedeHF registry.
• This biobank will enable studies on HF disease mechanisms and treatment responses.
• It will support precision medicine, identify novel drug targets, and structure biobanking for Registry-based Randomized Controlled Trials.